Galenica AG, previously Galenica Sante Ltd, is a Switzerland-based healthcare services and products provider. The Company's business i divided into three business sectors: Retail, Products & Brands, and Services. The Company manages a locally established pharmacies network in Switzerland. It develops and distributes its own product portfolio, as well as cooperates with a range of business partners, such as Pierre Fabre, Ales Groupe and Vitor Consumer Health for marketing and distribution of such brands as Perskindol, Triofan, A-Derma, Lierac, Phyto, Anti-Brumm and Algifor.
Galenica Sante's Services business sector is responsible for management of such logistics sector companies as Galexis, Unione Farmaceutica Distribuzione, Alloga and Medifilm..
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 64.9K | 
| Three Month Average Volume | 1.4M | 
| High Low | |
| Fifty-Two Week High | 78.15 CHF | 
| Fifty-Two Week Low | 65.1 CHF | 
| Fifty-Two Week High Date | 26 Feb 2024 | 
| Fifty-Two Week Low Date | 20 Oct 2023 | 
| Price and Volume | |
| Current Price | 73.65 CHF | 
| Beta | 0 | 
| Relative Price Change | |
| Four Week Relative Price Change | -8.01% | 
| Thirteen Week Relative Price Change | -4.86% | 
| Twenty-Six Week Relative Price Change | -9.96% | 
| Fifty-Two Week Relative Price Change | -6.14% | 
| Year-to-Date Relative Price Change | -9.34% | 
| Price Change | |
| One Day Price Change | 0.14% | 
| Thirteen Week Price Change | -1.41% | 
| Twenty-Six Week Price Change | -2.58% | 
| Five Day Price Change | 1.87% | 
| Fifty-Two Week Price Change | 4.91% | 
| Year-to-Date Price Change | 1.24% | 
| Month-to-Date Price Change | -3.66% | 
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 29.52749 CHF | 
| Book Value Per Share (Most Recent Quarter) | 28.21805 CHF | 
| Tangible Book Value Per Share (Last Fiscal Year) | 7.88478 CHF | 
| Tangible Book Value Per Share (Most Recent Quarter) | 6.01611 CHF | 
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | 6.15958 CHF | 
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 75.07796 CHF | 
| Revenue Per Share (Trailing Twelve Months) | 76.00853 CHF | 
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | 2.2 CHF | 
| Dividend Per Share (Trailing Twelve Months) | 2.2 CHF | 
| Dividend Per Share (5 Year) | 2.02 CHF | 
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | 3.30532 CHF | 
| Excluding Extraordinary Items (Trailing Twelve Months) | 3.39863 CHF | 
| Normalized (Last Fiscal Year) | 3.29393 CHF | 
| Basic Excluding Extraordinary Items (Last Fiscal Year) | 3.30842 CHF | 
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | 3.40204 CHF | 
| Including Extraordinary Items (Last Fiscal Year) | 5.71936 CHF | 
| Including Extraordinary Items (Trailing Twelve Months) | 3.55038 CHF | 
| Cash | |
| Cash Per Share (Last Fiscal Year) | 2.331 CHF | 
| Cash Per Share (Most Recent Quarter) | 1.3956 CHF | 
| Cash Flow Per Share (Last Fiscal Year) | 5.40197 CHF | 
| Cash Flow Per Share (Trailing Twelve Months) | 5.50564 CHF | 
| Free Cash Flow Per Share (Trailing Twelve Months) | 1.427 CHF | 
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | 3 | 
| Cash Flow Revenue (Trailing Twelve Months) | 2 | 
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | 5.37% | 
| Pretax Margin (Last Fiscal Year) | 5.20% | 
| Pretax Margin (5 Year) | 5.35% | 
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 27.81% | 
| Gross Margin (Trailing Twelve Months) | 27.68% | 
| Gross Margin (5 Year) | 26.37% | 
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | 5.32% | 
| Operating Margin (Trailing Twelve Months) | 5.51% | 
| Operating Margin (5 Year) | 5.47% | 
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | 4.42% | 
| Net Profit Margin (Trailing Twelve Months) | 4.49% | 
| Net Profit Margin (5 Year) | 4.40% | 
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 9.33% | 
| Tangible Book Value (5 Year) | 19.45% | 
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -2.82% | 
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 2.64% | 
| Revenue Growth (3 Year) | 3.43% | 
| Revenue Change (Trailing Twelve Months) | 2.97% | 
| Revenue Per Share Growth | 3.10% | 
| Revenue Growth (5 Year) | 2.49% | 
| Capital Spending Debt | |
| Capital Spending (5 Year) | 9.99% | 
| Total Debt (5 Year) | 13.54% | 
| Dividends | |
| Dividend Growth (3 Year) | 6.92% | 
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 6.29% | 
| EPS Change (Trailing Twelve Months) | 11.61% | 
| EPS Growth (3 Year) | 1.93% | 
| EPS Growth (5 Year) | -1.71% | 
| EBITDA | |
| EBITDA (5 Year) | 15.00% | 
| EBITDA (5 Year Interim) | 10.95% | 
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -1.06% | 
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 9 | 
| Price to Tangible Book (Most Recent Quarter) | 12 | 
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | 94 | 
| Price to Free Cash Per Share (Trailing Twelve Months) | 52 | 
| Net Debt | |
| Net Debt (Most Recent Quarter) | 831.4M | 
| Net Debt (Last Fiscal Year) | 658.7M | 
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 1 | 
| Price to Sales (Trailing Twelve Months) | 1 | 
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | 22 | 
| PE Normalized (Last Fiscal Year) | 22 | 
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | 22 | 
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 27 | 
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 17 | 
| PE Including Extraordinary Items (Trailing Twelve Months) | 21 | 
| Dividends | |
| Dividend Yield (5 Year) | 3.01% | 
| Dividend Yield | 2.99% | 
| Current Dividend Yield | 2.99% | 
| Price to Book | |
| Price to Book (Last Fiscal Year) | 2 | 
| Price to Book (Most Recent Quarter) | 3 | 
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 44 | 
| Long Term Debt to Equity (Most Recent Quarter) | 52 | 
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | 66.21% | 
| Payout Ratio (Trailing Twelve Months) | 64.36% | 
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 1 | 
| Quick Ratio (Most Recent Quarter) | 1 | 
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | 52 | 
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | 55 | 
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 1 | 
| Current Ratio (Most Recent Quarter) | 1 | 
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | 39.1M | 
| Free Cash Flow (Trailing Twelve Months) | 71.2M | 
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | 27 | 
| Net Interest Coverage (Trailing Twelve Months) | 369 | 
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 53 | 
| Total Debt to Equity (Most Recent Quarter) | 64 | 
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | 5.91% | 
| Return on Assets (Trailing Twelve Months) | 5.86% | 
| Return on Assets (5 Year) | 6.54% | 
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | 12.14% | 
| Return on Equity (Trailing Twelve Months) | 12.42% | 
| Return on Equity (5 Year) | 13.76% | 
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | 8.40% | 
| Return on Investment (Trailing Twelve Months) | 7.96% | 
| Return on Investment (5 Year) | 8.97% |